TROSYD UNGUEZ SOLUZ 12ML 28%

TROSYD

active ingredients

TROSYD 1% Cream 1 g cream contains: Active ingredient: Tioconazole 10 mg TROSYD 1% Skin dust 100 g of powder contain: Active ingredient: Tioconazole 1 g TROSYD 1% Emulsion of skin 100 g emulsion contain: Active ingredient: Tioconazole 1 g TROSYD 28% Skin solution for ointment use 100 g of solution contain: Active ingredient: Tioconazole 28 g TROSYD 1% Skin Solution Each bag of 10 gr solution contains: Active ingredient: Tioconazole 0.10 g Excipients with known effects: cetostearilic alcohol and propylene glycol. For the full list of excipients, see paragraph 6.1.

Excellent

Trosyd 1% Cream: polysorbate 60, monostearate sorbitan, cetostearilic alcohol, 2-ottildodecanol, cetilical ester wax, benzilic alcohol, purified water. Trosyd 1% Skin dust: talc, magnesium myristat, kaolin, silica precipitated. Trosyd 1% Skin emulsion: emulsifier wax, cetilic alcohol, cetilstearilic alcohol, coconut oil, glycerylstearate and palmitate, propylene glycol, benzilic alcohol, purified water. Trosyd 28% Skin solution for ointment use: undecilenic acid, ethyl acetate. Trosyd 1% Skin Solution: monoethanolamine laurilsulfate, lecithinamide, polyglycolum, undebenzofene, lactic acid, lipoesse lenitivo, purified water.

Therapeutic indications

TROSYD 1% Cream - 1% Skin dust - 1% Skin emulsion Dermatomycosis caused by dermatophytes, yeasts and other thyoconazole-sensitive mycetes. Skin infections caused by Gram-positive bacteria sensitive to the drug. For the concomitant antifungal and antibacterial activity, it is particularly indicated in mixed skin infections. TROSYD 28% Skin solution for ointment use Onicomicosis caused by dermatophytes and yeasts. For the concomitant antibacterial activity, it is particularly indicated in mixed nail infections. TROSYD 1% Skin Solution A topical antifungal treatment of skin infections caused by mycetes (dermatoids and yeasts), although associated with overinfections from Gram-positive bacteria sensitive to the medicinal product, as an adjuvant to therapy with other specific topical preparations. The skin solution allows for greater ease of application in the most extensive dermatomycosis and explicates a medicated detersion of the glabra or hairy skin. In addition, allowing the treatment of a wide skin surface, it makes it possible to eliminate the pathogen not only where morphological skin variations are detectable but also where the skin is apparently healthy.

Contraindications

Hypersensitivity to the active ingredient or any of the other components of this medicinal product listed in the paragraph 6.1. Trosyd 1% Skin Solution is contraindicated in pregnancy (see paragraph 4.6).

Population

Population TROSYD1% Cream - 1% Powder - 1% Skin emulsion The medicine should be applied by a slight massage twice a day, morning and evening, on the skin sliced and on the immediately surrounding one. The duration of treatment required to obtain healing varies from patient to patient and in relation to infecting agent and the home of infection. 7-day treatment is usually enough to get healing in most patients with Pityriasis versicolor, while up to 6 weeks of treatment may be necessary in case of severe forms of treatment Tinea pedis (athlete foot), especially with regard to the chronic hyperchratosic clinical variety. The duration of treatment required for dermatophytic infections to other localizations (body, skin folds) for Candidiasis and Eritrasma is usually between 2 and 4 weeks. Trosyd 28% Skin solution for ointment use The medicine should be applied on the infected nail and in the periungueal region twice a day, morning and evening, using the appropriate brush. The duration of treatment required to obtain healing varies from patient to patient, and is related to the infecting agent and the extent of injury. Usually therapy can last on average up to 6 months, but can be prolonged up to a year. Trosyd 1% Skin Solution The medicine should be applied once a day. The use of TROSYD 1% cutaneous solution must be done together with concomitant topical antifungal treatment, applied after the use of the solution. The duration of treatment required to obtain healing varies in relation to the infecting agent and the home of infection and is usually between two and four weeks. According to the doctor, treatment with the skin solution can be protracted even after the end of other topical specific therapies in order to reduce the risk of relapse. Pediatric population There is no security and effectiveness data TROSYD in children and teenagers. Method of administration Trosyd 1% Cream - 1% Powder - 1% Skin emulsion - In intertrigo areas TROSYD 1% Cream should be applied in small quantities and well spread, to avoid maceration phenomena. - TROSYD 1% Skin dust is available in a container with which it can be directly applied in a uniform layer. - TROSYD 1% Emulsion of skin must be applied with the tip of the fingers and with a swab of ovate. Trosyd 28% Skin solution for ointment use The solvent contained in Trosyd dries in 5 minutes leaving a thin transparent and oily film. Although this film is accidentally removed this does not decrease the activity of the drug, and therefore it is not necessary to apply it again. It is recommended not to use an occlusive bandage. Trosyd 1% Skin Solution It should be applied as a liquid detergent, and must be rinsed with water waiting for a few minutes. Use the amount of solution necessary in relation to the skin surface to be treated, because in contact with the skin forms a foamy solution.

Conservation

This medicine does not require any special condition of conservation.

Warnings

The application of medicinal products for topical use, especially if protracted, can give rise to awareness phenomena.Important information about some excipients: TROSYD 1% Cream - 1% Skin emulsion contain cetosterial alcohol that can cause local skin reactions (e.g. contact dermatitis). TROSYD 1% Skin emulsion contains propylene glycol that can cause skin irritation.

Interactions

Not so far known interactions or incompatibility with other medicinal products

Effects

In very rare cases a slight and transitory local irritation was observed. However, in the presence of hypersensitivity reactions, you will have to stop treatment and establish appropriate therapy. Reporting of suspicious adverse reactions The reporting of suspicious adverse reactions that occur after the authorization of the medicinal product is important, as it allows continuous monitoring of the benefit/risk ratio of the medicinal product. Healthcare workers are required to report any suspected adverse reaction via the national reporting system at the address www.agenziafarmaco.gov.it/it/responsabili.

Overdosing

No overdose has been reported so far.

There are no adequate and well-controlled studies on the use of pregnant or nursing medicine. Therefore the medicinal product must be used only in case of need, under the direct control of the doctor, after evaluating the expected benefit for the mother in relation to the possible risk for the fetus or for the infant. Trosyd 28% cutaneous solution for ointment use: although systemic absorption after topical administration is negligible, however, since the treatment of onicomycosis can last for many months, the use of Trosyd cutaneous solution for ointment in pregnancy is contraindicated.

Source: Farmadati